Protein concentration levels in the plasma were assessed by electrochemiluminometric immunoassay for the in vitro quantitative determination of GFAP in human serum and plasma (Elecsys® GFAP prototype test), and they were higher in GBM patients compared to controls. This evidence concerns the gene GFAP and glioblastoma.